SG11202106768RA - Anti-pd-l1 binding proteins and methods of use thereof - Google Patents
Anti-pd-l1 binding proteins and methods of use thereofInfo
- Publication number
- SG11202106768RA SG11202106768RA SG11202106768RA SG11202106768RA SG11202106768RA SG 11202106768R A SG11202106768R A SG 11202106768RA SG 11202106768R A SG11202106768R A SG 11202106768RA SG 11202106768R A SG11202106768R A SG 11202106768RA SG 11202106768R A SG11202106768R A SG 11202106768RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- binding proteins
- proteins
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785667P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068826 WO2020140090A1 (en) | 2018-12-27 | 2019-12-27 | Anti-pd-l1 binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106768RA true SG11202106768RA (en) | 2021-07-29 |
Family
ID=71125770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106768RA SG11202106768RA (en) | 2018-12-27 | 2019-12-27 | Anti-pd-l1 binding proteins and methods of use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220056137A1 (he) |
| EP (1) | EP3902563A4 (he) |
| JP (1) | JP2022516072A (he) |
| KR (1) | KR20210121047A (he) |
| CN (1) | CN113631188A (he) |
| AU (1) | AU2019413690A1 (he) |
| BR (1) | BR112021012688A2 (he) |
| CA (1) | CA3124979A1 (he) |
| IL (1) | IL284364A (he) |
| MX (1) | MX2021007846A (he) |
| SG (1) | SG11202106768RA (he) |
| WO (1) | WO2020140090A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022339953A1 (en) * | 2021-09-03 | 2024-02-29 | Novarock Biotherapeutics, Ltd. | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2546333T3 (es) * | 2005-07-01 | 2015-09-22 | E. R. Squibb & Sons, L.L.C. | Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada |
| WO2011066389A1 (en) * | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| ES2753360T3 (es) * | 2014-05-29 | 2020-04-08 | Spring Bioscience Corp | Anticuerpos contra PD-L1 y usos de los mismos |
| US10435470B2 (en) * | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| US10336824B2 (en) * | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| BR112021012667A2 (pt) * | 2018-12-27 | 2022-01-11 | Gigagen Inc | Proteínas de ligação anti-pd-1 e métodos de uso destas |
-
2019
- 2019-12-27 US US17/418,768 patent/US20220056137A1/en active Pending
- 2019-12-27 SG SG11202106768RA patent/SG11202106768RA/en unknown
- 2019-12-27 WO PCT/US2019/068826 patent/WO2020140090A1/en unknown
- 2019-12-27 CA CA3124979A patent/CA3124979A1/en not_active Abandoned
- 2019-12-27 AU AU2019413690A patent/AU2019413690A1/en not_active Abandoned
- 2019-12-27 MX MX2021007846A patent/MX2021007846A/es unknown
- 2019-12-27 KR KR1020217023742A patent/KR20210121047A/ko unknown
- 2019-12-27 JP JP2021537083A patent/JP2022516072A/ja active Pending
- 2019-12-27 BR BR112021012688-0A patent/BR112021012688A2/pt not_active Application Discontinuation
- 2019-12-27 CN CN201980092751.1A patent/CN113631188A/zh active Pending
- 2019-12-27 EP EP19902067.8A patent/EP3902563A4/en not_active Withdrawn
-
2021
- 2021-06-24 IL IL284364A patent/IL284364A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL284364A (he) | 2021-08-31 |
| JP2022516072A (ja) | 2022-02-24 |
| EP3902563A1 (en) | 2021-11-03 |
| MX2021007846A (es) | 2021-10-26 |
| CA3124979A1 (en) | 2020-07-02 |
| BR112021012688A2 (pt) | 2021-09-08 |
| WO2020140090A9 (en) | 2020-07-23 |
| EP3902563A4 (en) | 2022-12-28 |
| AU2019413690A1 (en) | 2021-08-12 |
| US20220056137A1 (en) | 2022-02-24 |
| CN113631188A (zh) | 2021-11-09 |
| WO2020140090A1 (en) | 2020-07-02 |
| KR20210121047A (ko) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281783A (he) | חלבונים קושרים מסוג SIRPa ושיטות שימוש בהם | |
| IL275782A (he) | חלבונים קושרי אנטיגן רב-ספציפיים ושיטות לשימוש בהם | |
| IL281683A (he) | חלבונים קושרי dll3 ושיטות לשימוש | |
| IL276731A (he) | נוגדנים נגד cd73 ושיטות לשימוש בהם | |
| IL278821A (he) | נוגדנים אנטי- sirpa ושיטות לשימוש בהם | |
| IL288071A (he) | חלבונים קושרי epcamושיטות לשימוש | |
| IL261666A (he) | חלבונים קשורים ושיטות לשימוש בהם | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| EP3635013A4 (en) | NECTIN-4 BINDING PROTEINS AND PROCESSES FOR USE | |
| IL269074A (he) | חלבונים הקושרים אנטיגנים אנטי-tigit ושיטות לשימוש בהם | |
| IL284157A (he) | חלבונים קושרים כנגד pd-1 ושיטות לשימוש בהם | |
| IL279201A (he) | חלבונים קושרים רב-ספציפיים ושיטות לשימוש בהם | |
| ZA202300348B (en) | Anti-sortilin antibodies and methods of use thereof | |
| IL284156A (he) | חלבונים קושרים כנגד ctla-4 ושיטות לשימוש בהם | |
| IL277212A (he) | נוגדנים אנטי-klk5 ושיטות לשימוש | |
| IL279648A (he) | נוגדנים אנטי-sirp-בתא 1 ושיטות לשימוש בהם | |
| IL283884A (he) | נוגדנים כנגד il-36 ושיטות לשימוש בהם | |
| IL280338A (he) | נוגדנים אנטי- siglec-5ושיטות לשימוש בהם | |
| IL279227A (he) | נוגדנים אנטי- siglec-7 ושיטות לשימוש בהם | |
| IL284364A (he) | חלבונים קושרים כנגד pd-l1 ושיטות לשימוש בהם |